DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY

This adverse event was reported 383 times

These drugs are most commonly taken by patients reporting DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY:

# Drug Count
0 RITUXIMAB 210
1 CYCLOPHOSPHAMIDE 192
2 DOXORUBICIN 162
3 ETOPOSIDE 140
4 PREDNISONE 129
5 CISPLATIN 118
6 CYTARABINE 115
7 DEXAMETHASONE 114
8 DEXAMETHASONE 1.5 MG 114
9 IFOSFAMIDE 87
See all common drugs associated with DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY

DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 POLATUZUMAB VEDOTIN 57 0.0320
1 TAFASITAMAB-CXIX 2 0.0153
2 SELINEXOR 35 0.0095
3 CASPOFUNGIN ACETATE 33 0.0086
4 HYALURONIDASE (HUMAN RECOMBINANT) 1 0.0071
5 RITUXIMAB AND HYALURONIDASE 2 0.0067
6 ALBUMIN HUMAN 15 0.0066
7 IFOSFAMIDE 87 0.0066
8 DAPTOMYCIN 33 0.0032
9 VINCRISTINE SULFATE 65 0.0032
See all drugs enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY

DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Endoglycosidase [EPC] 8 0.0055
1 Lipopeptide Antibacterial [EPC] 33 0.0032
2 Topoisomerase Inhibitor [EPC] 140 0.0029
3 CD20-directed Cytolytic Antibody [EPC] 215 0.0013
4 Alkylating Drug [EPC] 209 0.0013
5 Platinum-based Drug [EPC] 191 0.0012
6 Nucleoside Metabolic Inhibitor [EPC] 157 0.0007
7 CD30-directed Immunoconjugate [EPC] 4 0.0007
8 Aldosterone Antagonist [EPC] 34 0.0003
9 Vitamin K [EPC] 2 0.0003
See all drug classes enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY